Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year Update
Attention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in childhood. Current treatment options for ADHD include pharmacological treatment (stimulants, non-stimulants, anti-depressants, anti-psychotics), psychological treatment (behavioral therapy with or witho...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Medical Publishing
2022-07-01
|
| Series: | Health Psychology Research |
| Online Access: | https://doi.org/10.52965/001c.37018 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823857484535693312 |
|---|---|
| author | Hannah W Haddad Paul B. Hankey Jimin Ko Zahaan Eswani Pravjit Bhatti Amber N. Edinoff Adam M. Kaye Alan D. Kaye |
| author_facet | Hannah W Haddad Paul B. Hankey Jimin Ko Zahaan Eswani Pravjit Bhatti Amber N. Edinoff Adam M. Kaye Alan D. Kaye |
| author_sort | Hannah W Haddad |
| collection | DOAJ |
| description | Attention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in childhood. Current treatment options for ADHD include pharmacological treatment (stimulants, non-stimulants, anti-depressants, anti-psychotics), psychological treatment (behavioral therapy with or without parent training, cognitive training, neurofeedback), and complementary and alternative therapies (vitamin supplementation, exercise). Central nervous system (CNS) stimulants are the primary pharmacological therapy used in treatment; however, these stimulant drugs carry a high potential for abuse and severe psychological/physical dependence. Viloxazine, a non-stimulant medication without evidence of drug dependence, is a selective norepinephrine reuptake inhibitor that has historically been prescribed as an anti-depressant medication. The extended-release (ER) form was approved by the US Food and Drug Administration (FDA) in April 2021 for the treatment of ADHD in pediatric patients aged 6-17 years. Phase 2 and 3 randomized control trials have demonstrated significant efficacy of viloxazine in improving ADHD symptoms versus placebo. Related to its long-standing use as an antidepressant, the safety profile and pharmacokinetics of viloxazine are well understood. Viloxazine appears to be a suitable alternative to current standard-of-care pharmacotherapy for ADHD, but the further investigation remains to be done in comparing its efficacy to that of current treatments. |
| format | Article |
| id | doaj-art-3f77543bf5234cf098188ea0b5b54855 |
| institution | Kabale University |
| issn | 2420-8124 |
| language | English |
| publishDate | 2022-07-01 |
| publisher | Open Medical Publishing |
| record_format | Article |
| series | Health Psychology Research |
| spelling | doaj-art-3f77543bf5234cf098188ea0b5b548552025-02-11T20:30:39ZengOpen Medical PublishingHealth Psychology Research2420-81242022-07-01102Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year UpdateHannah W HaddadPaul B. HankeyJimin KoZahaan EswaniPravjit BhattiAmber N. EdinoffAdam M. KayeAlan D. KayeAttention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in childhood. Current treatment options for ADHD include pharmacological treatment (stimulants, non-stimulants, anti-depressants, anti-psychotics), psychological treatment (behavioral therapy with or without parent training, cognitive training, neurofeedback), and complementary and alternative therapies (vitamin supplementation, exercise). Central nervous system (CNS) stimulants are the primary pharmacological therapy used in treatment; however, these stimulant drugs carry a high potential for abuse and severe psychological/physical dependence. Viloxazine, a non-stimulant medication without evidence of drug dependence, is a selective norepinephrine reuptake inhibitor that has historically been prescribed as an anti-depressant medication. The extended-release (ER) form was approved by the US Food and Drug Administration (FDA) in April 2021 for the treatment of ADHD in pediatric patients aged 6-17 years. Phase 2 and 3 randomized control trials have demonstrated significant efficacy of viloxazine in improving ADHD symptoms versus placebo. Related to its long-standing use as an antidepressant, the safety profile and pharmacokinetics of viloxazine are well understood. Viloxazine appears to be a suitable alternative to current standard-of-care pharmacotherapy for ADHD, but the further investigation remains to be done in comparing its efficacy to that of current treatments.https://doi.org/10.52965/001c.37018 |
| spellingShingle | Hannah W Haddad Paul B. Hankey Jimin Ko Zahaan Eswani Pravjit Bhatti Amber N. Edinoff Adam M. Kaye Alan D. Kaye Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year Update Health Psychology Research |
| title | Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year Update |
| title_full | Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year Update |
| title_fullStr | Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year Update |
| title_full_unstemmed | Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year Update |
| title_short | Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year Update |
| title_sort | viloxazine a non stimulant norepinephrine reuptake inhibitor for the treatment of attention deficit hyperactivity disorder a 3 year update |
| url | https://doi.org/10.52965/001c.37018 |
| work_keys_str_mv | AT hannahwhaddad viloxazineanonstimulantnorepinephrinereuptakeinhibitorforthetreatmentofattentiondeficithyperactivitydisordera3yearupdate AT paulbhankey viloxazineanonstimulantnorepinephrinereuptakeinhibitorforthetreatmentofattentiondeficithyperactivitydisordera3yearupdate AT jiminko viloxazineanonstimulantnorepinephrinereuptakeinhibitorforthetreatmentofattentiondeficithyperactivitydisordera3yearupdate AT zahaaneswani viloxazineanonstimulantnorepinephrinereuptakeinhibitorforthetreatmentofattentiondeficithyperactivitydisordera3yearupdate AT pravjitbhatti viloxazineanonstimulantnorepinephrinereuptakeinhibitorforthetreatmentofattentiondeficithyperactivitydisordera3yearupdate AT ambernedinoff viloxazineanonstimulantnorepinephrinereuptakeinhibitorforthetreatmentofattentiondeficithyperactivitydisordera3yearupdate AT adammkaye viloxazineanonstimulantnorepinephrinereuptakeinhibitorforthetreatmentofattentiondeficithyperactivitydisordera3yearupdate AT alandkaye viloxazineanonstimulantnorepinephrinereuptakeinhibitorforthetreatmentofattentiondeficithyperactivitydisordera3yearupdate |